The Other Patient: Care for the Caregivers
What Our Partners and Caregivers Carry on This Roller Coaster
Bottom Line Up Front (BLUF)
When a man is diagnosed with prostate cancer and embarks on treatment — whether surgery, radiation, androgen deprivation therapy (ADT), PSMA imaging, or the newest theranostics — his spouse or care partner shoulders a second, often invisible, patient journey alongside him. Research consistently shows that partners experience rates of anxiety and depression equal to or greater than patients, sacrifice thousands of hours of work and personal time, suffer significant sexual and intimacy losses, and receive far less clinical attention than their needs warrant. As prostate cancer treatment has grown more complex — now stretching across years of hormonal therapy and novel radioligand cycles — so too has the caregiver's burden. This article describes what our partners live with, what the science says about it, and what each of us can do to better recognize and support the person riding alongside us on this difficult road.
Introduction: Two People, One Diagnosis
Prostate cancer is the second most common cancer in American men. More than 300,000 new cases will be diagnosed this year alone. Behind each of those diagnoses stands at least one other person — a wife, a husband, a life partner — who did not choose this disease but must navigate every twist and turn of it.
When the urologist says "it's prostate cancer," we men tend to go into problem-solving mode. We research options. We compare PSA curves, Gleason scores, and treatment protocols. We focus on the next scan, the next injection, the next trial visit. That drive and focus is understandable — even necessary. But it can leave us blind to what is happening to the person sitting beside us in the waiting room.
"Partners of men diagnosed with prostate cancer face their own emotional struggles as they navigate additional caregiver responsibilities while concurrently adjusting to the diagnosis and coping with greater illness uncertainty."
That sentence comes from a 2024 systematic review published in the journal Cancer Nursing.1 It reflects what a growing body of research has been documenting for two decades and what the men in our IPCSG community know intuitively when they pause to think about it: our partners are on this roller coaster with us — and they often have no harness.
Anxiety, Depression, and the Weight of Uncertainty
A Spanish study published in Prostate Cancer examined rates of previously undetected depression and anxiety in prostate cancer patients and their wives. The investigators found that spouses suffered from clinically significant anxiety and depression at rates strikingly similar to those of the patients — and that these psychological conditions often went undetected by the medical team, whose attention was almost entirely directed at the man with cancer.2
This finding is echoed across many countries and cultures. In a 2024 meta-aggregation systematic review, Australian and Scottish researchers found that partners experience a distinct and multilayered emotional burden: fear of recurrence, anxiety about the future, grief over the loss of familiar roles, and profound loneliness — often in silence, because they feel they must "be strong" for their partner.1
A 2025 study published in Supportive Care in Cancer, drawing on data from couples in the United Kingdom between January and August 2024, confirmed that both patients and partners face significant psychological distress, but the routes are different. Patients tend to struggle with threats to their sense of masculinity and bodily integrity. Partners tend to struggle with caregiver stress, fear, and the erosion of intimacy — often without anyone asking how they are doing.6
Androgen Deprivation Therapy: When the Man Changes
Of all the treatments in prostate cancer's arsenal, androgen deprivation therapy (ADT) — the use of medications to suppress testosterone — may be the one that most profoundly affects the couple as a unit. ADT is used at nearly every stage of the disease, from high-risk localized cancer to metastatic castration-resistant prostate cancer (mCRPC), and its reach has expanded with the introduction of next-generation agents like enzalutamide, abiraterone, darolutamide, and apalutamide.
For a woman who has lived with her husband for twenty, thirty, or forty years, ADT can feel like living with a different person. A landmark review published in Cancer documented multiple adverse psychological effects of ADT that directly affect the couple: increased emotional lability (mood swings and tearfulness), depressed mood, reduced libido, erectile dysfunction, cognitive changes, and a diminished sense of masculinity that can alter how a man relates to his wife, his friends, and himself.7
Importantly, partners feel these changes too — and often more acutely. A study of 295 prostate cancer patients and 84 of their partners found that partners on ADT reported even greater declines in the patient's mood than the patients themselves reported, suggesting that the partner is absorbing the emotional impact of the treatment change from the outside, without the internal compensatory mechanisms that the patient may experience.4
The cognitive side effects of ADT add another layer. A 2023 review in the journal Medicina confirmed growing evidence that ADT is associated with impairment in executive function, memory, and spatial abilities — the very cognitive domains needed to manage a household, navigate finances, and make complex medical decisions. When the man with cancer becomes cognitively less reliable, the partner typically compensates quietly, shouldering a larger share of household and decision-making responsibilities without acknowledgment.8
Meanwhile, the medical system rarely screens caregivers for depression. A landmark study of 37,388 men with prostate cancer on ADT found that 10.6% were diagnosed with a new depressive or anxiety disorder after starting ADT — yet nearly half received no documented mental health treatment.3 If the patient's mental health goes largely unaddressed, his partner's is nearly invisible to the clinical system entirely.
Surgery, Radiation, and the Aftermath Partners Navigate
Prostate cancer treatment often begins with either radical prostatectomy (robotic or open surgery) or radiation therapy (external beam, brachytherapy, or stereotactic body radiation). For partners, the peri-operative and early recovery period introduces a new role: acute caregiver. They manage drain tubes, catheter care, medication schedules, dietary restrictions, and the emotional weight of watching someone they love in pain and vulnerability.
Research from the National Cancer Institute confirms that spousal and partner caregivers provide roughly half of all unpaid cancer care — and that this caregiving comes with significant personal costs.9 A study published in Supportive Care in Cancer estimated that partner caregivers gave up an average of 134 hours per year of paid employment in the first twelve months following a prostate cancer diagnosis. Translated to 2009 dollars, the average annual economic burden per caregiver was $6,063 — and if that estimate were scaled to all 1.8 million Americans then living with localized prostate cancer, the societal cost would have exceeded $11 billion annually, even before accounting for advanced disease.5
The urinary and sexual side effects of surgery and radiation are well-known to patients. Less recognized is their effect on partners. A 2024 systematic review in Supportive Care in Cancer found that sexual and intimacy concerns are among the highest-ranked unmet needs for patients across all treatment types — and that most women partners feel effectively "invisible" in the clinical encounter, unable to ask questions, unable to have their own grief over the loss of sexual intimacy acknowledged.10
"Without intimacy, women expressed feelings of grief and isolation." — Analysis of female partner postings, UsTOO Prostate Cancer Online Community11
An analysis of posts by female caregivers to the UsTOO online prostate cancer community found that intimacy — not necessarily intercourse — was the central concern. Partners grieved the loss of physical closeness, affectionate touch, and emotional connection far more than the mechanics of sex. And they felt conflicted about bringing it up, sensing that raising sexual concerns when their partner was fighting cancer felt somehow selfish or inappropriate.11
PSA Anxiety, Scans, and the Space Between Results
Anyone who has lived in the world of active prostate cancer treatment knows "PSA anxiety" — the dread that builds in the days and weeks before a blood draw, and the suspended breath as results load on the patient portal. What is less often discussed is that this anxiety is shared by the partner, often with no support structure of her own.
A 2025 study from Memorial Sloan Kettering Cancer Center examined anxiety and depression in patient-partner dyads during active surveillance. While baseline anxiety levels were correlated within couples, the researchers found that each person's emotional state over time was driven more by their own individual psychology than by direct emotional contagion from the partner — suggesting that each person in the couple needs their own psychological support, not just as an extension of the patient's care.12
The cadence of modern prostate cancer monitoring — PSA every three months, periodic bone scans, CT scans, PSMA PET/CT imaging — creates a cycle of anticipation, anxiety, result-absorption, and brief relief before the next cycle begins. Partners ride every one of those cycles. The ASCO guideline on systemic therapy for mCRPC explicitly acknowledges that "caregiver and community support are essential to optimizing prostate cancer outcomes" — but translating that acknowledgment into actual clinical resources for caregivers remains inconsistent at best.13
The New Era of Theranostics: More Hope, More Complexity
Perhaps nothing in prostate cancer has generated more hope in recent years than theranostics — the combined use of diagnostic imaging and targeted radioligand therapy. Lutetium-177 PSMA (Pluvicto), approved by the FDA in 2022 for mCRPC, received an expanded indication in March 2025 for use after androgen receptor pathway inhibitor therapy, earlier in the disease course than before.14 Investigational alpha-emitting agents like Actinium-225 PSMA are being studied in trials including the CONVERGE-01 study at UCSD and other academic centers.
For patients, this is exciting — new options where options were once scarce. For caregivers, theranostics introduces a new dimension of complexity and fear. The word "radioactive" alone carries psychological freight. Partners must understand radiation safety protocols: maintaining distance from the patient in the days following a lutetium infusion, avoiding prolonged close physical contact, and following specific guidance about shared sleeping arrangements and toilet use. These are not trivial lifestyle interruptions — they strike directly at the physical closeness that sustains a relationship.
A 2025 multi-national survey of patients with mCRPC and their caregivers, published in Future Oncology, found that both groups experienced significant emotional burdens around advanced-stage treatment — including fear of disease progression, uncertainty about how long treatments would continue to work, and a persistent sense that neither patients nor caregivers were receiving adequate emotional and informational support from their medical teams.15
Theranostics also involves repeated clinic visits, often to specialized nuclear medicine centers that may not be local, adding logistical burden — travel, time away from work, lodging — that falls heavily on the caregiver partner. As the VISION trial established lutetium-PSMA's survival benefit, and as next-generation theranostics like Actinium-225 advance through Phase I/II trials, the treatment cycles are likely to become longer and more complex, not shorter. The caregiver's journey lengthens with each new therapy line.
What Happens to the Marriage and Partnership
Prostate cancer does not occur in a man; it occurs in a couple. Research consistently confirms that marital and partnership satisfaction, sexual functioning, and overall relationship quality are affected at every stage of the disease and often for years beyond active treatment.
A 2025 systematic review and meta-analysis published in BMC Nursing examined 19 randomized controlled trials and 22 different interventions for prostate cancer patient-caregiver dyads. The review found that dyadic interventions — those that address both the patient and the caregiver simultaneously — significantly improved psychosocial outcomes, sexual health, and relationship functioning, outperforming individual-focused approaches.16 The key ingredient was joint participation: when both people were in the room and both voices were heard, outcomes improved.
Northouse and colleagues, in a landmark study of advanced prostate cancer (APC) survivors and their spousal caregivers, found that the physical and mental health of the caregiver spouse directly predicted the patient's own marital satisfaction — not just the caregiver's own wellbeing. When the partner is struggling, the patient suffers too.17 The couple truly is a system.
A National Cancer Institute-funded program on Intimacy-Enhancing Couples Interventions (IEC) found that teaching communication and intimacy-building skills to couples coping with localized prostate cancer reduced both patient and partner distress. Critically, the benefit was greatest among couples who had been married longer and among men with more traditional notions of masculinity — precisely the profile of many men in our community.18
What We, As Patients, Can Do
The research is clear, and so is the human logic: our partners need us to see them. Not just as support systems for our disease, but as full participants in a shared experience that is also hard for them. Here are some concrete, evidence-supported steps.
Ask your doctor to include your partner in the conversation. The 2022 AUA/ASTRO guideline on clinically localized prostate cancer explicitly recommends that clinicians encourage patients to engage with "professional or community-based resources" — yet most clinical encounters still focus almost entirely on the patient. Ask your oncologist, urologist, or nuclear medicine team to address your partner directly: "What should she know? What should she watch for? How is she doing?"
Let her have her own voice — not just yours. The Prostate Cancer Foundation has documented that many female partners feel unable to ask healthcare providers their own questions during appointments. Consider having separate time — even just five minutes — where your partner can speak with a nurse or navigator without filtering through you.
Acknowledge the sexual and intimacy loss openly. Research shows that couples who communicate openly about sexual problems after treatment have significantly better relationship outcomes than those who stay silent.19 The loss is real and it belongs to both of you. Naming it together matters.
Bring her to your support group. IPCSG and ZERO Prostate Cancer both offer resources and spaces for care partners. The 2024 ZERO+1 Caregiver Retreat produced video resources covering mental health, self-care, communicating with doctors, estate planning, and caregiver community-building — all available free online.20
Exercise together, if you can. A series of dyadic exercise trials, including the Exercising Together© program, have shown that partner-joined resistance training improves both patients' and caregivers' physical function, mood, and sense of teamwork.21 The exercise itself matters; so does the shared activity.
Acknowledge the economic sacrifice. If your partner has reduced work hours, taken on additional household responsibilities, or reorganized her life around your treatment schedule, say so explicitly. The research confirms the economic burden is real and significant — and that recognition matters even when compensation is not possible.
Resources for Caregivers and Care Partners
- ZERO Prostate Cancer – Caregiver Resources (2024): Videos, guides, peer support, and the ZERO Caregiver Guide. zerocancer.org/caregivers
- Prostate Cancer Foundation – Partner Sexual Quality of Life: Research summaries and guidance for couples. pcf.org
- National Cancer Institute – Informal Caregivers in Cancer (PDQ): Comprehensive clinical overview for caregivers. cancer.gov
- Family Caregiver Alliance – Family Care Navigator: State-by-state resource directory. caregiver.org
- UsTOO Prostate Cancer Support: Online community including spaces for partners. ustoo.org
- IPCSG: Our monthly meetings welcome partners. Dates and details at ipcsg.org
When She Won't Come to the Support Group — And That's Okay
Many of us have tried to bring our wives or partners to IPCSG meetings or similar support groups, only to be gently — or not so gently — turned down. It is easy to feel frustrated by this, or to interpret it as a lack of engagement with something that has become central to our own lives. But the resistance is usually more nuanced than it appears, and it deserves to be understood rather than overcome.
Partners who decline group participation tend to fall into recognizable patterns. Some are already living inside the disease every day — managing medications, appointments, dietary changes, emotional swings — and a room full of other people's medical details feels like more of the same weight, not relief. Others are private by temperament: the group dynamic, with strangers sharing difficult and intimate experiences, feels emotionally exposing in a way that doesn't suit their personality. And some are consciously or unconsciously maintaining a small zone of distance from the clinical machinery of the illness, which is actually a legitimate coping strategy. Keeping some part of daily life untouched by cancer is not avoidance — it can be self-preservation.
Research on caregiver coping styles confirms that partners use a wide range of strategies, and that no single approach — including joining a support group — is right for everyone. What matters is that the partner has some outlet, some form of support, even if it looks nothing like what we imagined.
If a group setting doesn't fit, several alternatives are worth considering:
One-on-one peer support. ZERO Prostate Cancer offers matched peer support connecting a care partner privately with another woman who has navigated a similar experience. No group dynamics, no room full of strangers — just a single conversation with someone who genuinely understands. This format works well for partners who are private but not isolated.
A couples counselor with oncology or chronic illness experience. This is not crisis intervention — it is a neutral space where both people in the relationship can speak freely about the experience they are sharing. A skilled counselor can help open conversations that feel too weighted to have at home, where one person is always the patient and the other is always the caregiver.
Self-directed learning. Many partners who resist groups are quite open to reading, listening, or watching on their own terms. A well-written article, a recorded talk, or a podcast episode about the caregiver experience can provide validation and information without requiring any performance of coping in front of others. The ZERO+1 Caregiver Retreat videos, available free online, were designed with exactly this kind of self-directed engagement in mind.
Simply asking what would help her. This is perhaps the most underused tool available to us. Research consistently shows that partners often feel their needs go unasked — that the entire system, including the patient, directs attention toward the man with cancer while the partner's own experience is assumed or overlooked. The question "What would actually help you?" — asked sincerely, without a predetermined answer in mind — can open a conversation that months of encouragement to attend a group never will.
The goal is not to get her to the meeting. The goal is to make sure she is not carrying this alone.
It is also worth reflecting honestly on what is driving our wish for her to attend. Sometimes it is genuine concern for her wellbeing. Sometimes it is the hope that shared participation will bring us closer, or that having her in the room will ease our own sense of guilt about the burden the disease places on her. Those are understandable impulses — but they are about us, not her. Meeting her where she is, in the coping style that actually fits her, is likely to do more for both of you than any particular program or group.
Conclusion: Seeing the Person in the Next Seat
In every waiting room, every nuclear medicine suite, every infusion center, there are two journeys happening. We, the patients, are acutely aware of our own. The research asks us — gently but firmly — to become more aware of the one happening in the chair right next to us.
Our partners did not choose prostate cancer. They did not choose the ADT mood swings, the post-surgical fatigue, the three-month PSA vigils, the radiation safety protocols, or the years of watching someone they love negotiate a disease with no guaranteed ending. They chose us. That is not a small thing. It deserves to be seen, named, and honored — not just in private gratitude, but in the way we share our medical appointments, the way we show up to support groups, and the way we ask our doctors to care for the whole family, not just the man with the elevated PSA.
Prostate cancer is a roller coaster. Our partners are riding it too. The least — and perhaps the most — we can do is reach over and hold their hand.
Verified Sources and Formal Citations
- Roberts C, Toohey K, Paterson C. "The Experiences and Unmet Supportive Care Needs of Partners of Men Diagnosed With Prostate Cancer: A Meta-aggregation Systematic Review." Cancer Nursing. Published online February 2, 2024. doi:10.1097/NCC.0000000000001172. https://pubmed.ncbi.nlm.nih.gov/36480350/
- López Teros A, et al. "Prevalence of Anxiety and Depression in Prostate Cancer Patients and Their Spouses: An Unaddressed Reality." Prostate Cancer. 2020. PMC7097760. https://pmc.ncbi.nlm.nih.gov/articles/PMC7097760/
- Tsao PA, et al. "Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy." The Oncologist. 2022;27(4):314. doi:10.1093/oncolo/oyac025. https://academic.oup.com/oncolo/article/27/4/314/6550091
- Donovan KA, et al. "Androgen deprivation therapy's impact on the mood of prostate cancer patients as perceived by patients and the partners of patients." Psycho-Oncology. 2015. doi:10.1002/pon.3962. PMID:26332203. https://pubmed.ncbi.nlm.nih.gov/26332203/
- Li C, Zeliadt SB, Hall IJ, et al. "Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective." Support Care Cancer. 2013;21(12):3461–69. PMC4535430. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535430/
- Exploring the role of psychological flexibility in relationship functioning among couples coping with prostate cancer: a cross-sectional study. Supportive Care in Cancer. Published February 13, 2025. doi:10.1007/s00520-025-09229-8. https://link.springer.com/article/10.1007/s00520-025-09229-8
- Donovan KA, Walker LM, Wassersug RJ, Thompson LMA, Robinson JW. "Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners." Cancer. 2015;121(24):4286–99. doi:10.1002/cncr.29672. PMID:26372364. https://pubmed.ncbi.nlm.nih.gov/26372364/
- Narayanan G, et al. "Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood." Medicina. 2024;60(1):77. doi:10.3390/medicina60010077. https://www.mdpi.com/1648-9144/60/1/77
- National Cancer Institute. "Informal Caregivers in Cancer (PDQ®) – Health Professional Version." Updated 2025. https://www.cancer.gov/about-cancer/coping/family-friends/family-caregivers-hp-pdq
- Arends RM, et al. "Tools supporting communication about changes in intimacy and sexuality among patients with cancer: a systematic review." Supportive Care in Cancer. 2024;32:109. doi:10.1007/s00520-023-08270-3. https://link.springer.com/article/10.1007/s00520-023-08270-3
- Wittmann D, et al. "Sexual Concerns of Female Partners of Prostate Cancer Patients: Novel Data from an Online Health Community." Abstract 163. Journal of Sexual Medicine. 2020;17(Supplement):S115–S116. doi:10.1016/j.jsxm.2019.11.160. https://www.sciencedirect.com/science/article/abs/pii/S1743609519316285
- Polland A, et al. "The interplay and influence of anxiety and depression among men with early-stage prostate cancer and their close allies." Published online November 2025. PMID:41205128. https://pubmed.ncbi.nlm.nih.gov/41205128/
- ASCO Expert Panel. "Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update." Journal of Clinical Oncology. 2025. doi:10.1200/JCO-25-00007. https://ascopubs.org/doi/10.1200/JCO-25-00007
- Novartis. "FDA Approves Novartis Radioligand Therapy Pluvicto® for Earlier Use in PSMA-Positive mCRPC." Press release, March 28, 2025. Referenced in: NCODA. "Prostate Cancer: Imaging and Therapy Options from an Oncology Perspective." November 2025. https://www.ncoda.org
- Jain R, et al. "Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey." Future Oncology. 2025;21:2053–2066. doi:10.1080/14796694.2025.2510890. https://www.tandfonline.com/doi/full/10.1080/14796694.2025.2510890
- Li X, et al. "The effectiveness of dyadic interventions for health outcomes of prostate cancer patients and informal caregivers: a systematic review and meta-analysis." BMC Nursing. Published February 3, 2025. doi:10.1186/s12912-025-02769-8. https://link.springer.com/article/10.1186/s12912-025-02769-8
- Northouse LL, et al. "Marital satisfaction of advanced prostate cancer survivors and their spousal caregivers: the dyadic effects of physical and mental health." PMID:20925137. https://pubmed.ncbi.nlm.nih.gov/20925137/
- Manne S, et al. National Cancer Institute Grant CA140297. "Intimacy-Enhancing Couples Intervention for Prostate Cancer." NCI DCCPS Funding History. https://maps.cancer.gov
- Prostate Cancer Foundation. "Impact of Prostate Cancer on Partners' Sexual Quality of Life." Updated June 2025. https://www.pcf.org/patient-support/side-effects/sexual-health/quality-of-life-questionnaire/
- ZERO Prostate Cancer. "Caregiver Resources" (includes 2024 ZERO+1 Caregiver Retreat videos). https://zerocancer.org/help-and-support/resources-for/caregivers
- Winters-Stone KM, et al. "Exercising Together©." Referenced in: Dyadic resistance training adaptation for Hispanic men with prostate cancer and their caregivers. Frontiers in Psychology. 2024. doi:10.3389/fpsyg.2024.1294546. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2024.1294546
- Bayer AG. "Challenges and Unmet Needs of Caregivers for Patients with Prostate Cancer: A US-based Quantitative Survey." Abstract IP04-31, AUA Annual Meeting 2025, Las Vegas. Press release April 16, 2025. https://www.businesswire.com
- AUA/ASTRO Guideline. "Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022)." Recommendation 44. https://www.auanet.org
Comments
Post a Comment